- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| NATIONAL VACCINATION PROGRAM – DPTP booster vaccination |
|---|
|
| Passive protection against whooping cough (pertussis) |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
No information available on dose adjustment in renal impairment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
After primary vaccination: Very common (> 10%): local reactions such as pain, redness and swelling at the injection site. Reduced appetite, fever, drowsiness, more easily irritated. Common (1-10%): abnormal crying, restlessness, viral infection, infection of the upper respiratory tract, bronchitis, conjunctivitis, coughing, vomiting, rhinitis. Uncommon (0.1-1%): Fatigue, abdominal pain, diarrhoea, obstipation, enteritis or gastroenteritis, sleepiness, infection, middle ear inflammation, eczema, dermatitis. Very rare (< 0.01%): convulsions, allergic reactions. After revaccination: fever (> 38%). Common (1-10%): diarrhoea, enteritis or gastroenteritis, candidiasis, middle ear inflammation, pharyngitis, dermatitis, rash. Uncommon (0.1-1%): sleeplessness, bronchial spasms, laryngitis, stridor. During the post-marketing phase, fainting or shock-like symptoms and anaphylactic reactions have been reported in other vaccines containing DTaP.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Consider the administration of vaccines containing whooping cough carefully if any of the following symptoms have occurred when previously given: high fever (> 40°C) within 48 hours of vaccination that is not attributable to any other cause; collapse or a shock-like condition within 48 hours of vaccination; continuous (≥ 3 hours) and inconsolable crying within 48 hours of vaccination; convulsions with or without fever within three days of vaccination. Be cautious if there is a history of progressive neurological conditions. Do not administer intravascularly under any circumstances. The immunogenicity of the vaccine can be reduced by immunosuppressive treatment or immunodeficiency. Triaxis Polio must not be given to people with incomplete or missing prior history of primary vaccination against diphtheria, tetanus or polio because it will be insufficiently effective.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Bacterial and viral vaccines, combined | ||
|---|---|---|
| J07CA09 | ||
| J07CA06 | ||
| J07CA01 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- GlaxoSmithKline BV, SPC Infanrix IPV RVG 34568, www.cbg-meb.nl, http://db.cbg-meb.nl/IB-teksten/h34568.pdf, (geraadpleegd 29 okt 2009)
- RIVM, Rijksvaccinatieprogramma: Vaccinatieschema, 3 december 2019
- GlaxoSmithKline BV, SmPC Boostrix Polio (RVG 35123 en 35124) 14-12-2018, www.geneesmiddeleninformatiebank.nl
- Sanofi Pasteur Europe , SmPC Triaxis Polio (RVG 27569) 23-06-2020, www.geneesmiddeleninformatiebank.nl
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
